[go: up one dir, main page]

WO2008012071A3 - Pharmaceutical compositions of nicotine and methods of use thereof - Google Patents

Pharmaceutical compositions of nicotine and methods of use thereof Download PDF

Info

Publication number
WO2008012071A3
WO2008012071A3 PCT/EP2007/006579 EP2007006579W WO2008012071A3 WO 2008012071 A3 WO2008012071 A3 WO 2008012071A3 EP 2007006579 W EP2007006579 W EP 2007006579W WO 2008012071 A3 WO2008012071 A3 WO 2008012071A3
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
compositions
present
methods
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/006579
Other languages
French (fr)
Other versions
WO2008012071A2 (en
Inventor
Carrara Dario Norberto R
Arnaud Grenier
Celine Besse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antares Pharma IPL AG
Original Assignee
Antares Pharma IPL AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/492,568 external-priority patent/US7387788B1/en
Application filed by Antares Pharma IPL AG filed Critical Antares Pharma IPL AG
Publication of WO2008012071A2 publication Critical patent/WO2008012071A2/en
Publication of WO2008012071A3 publication Critical patent/WO2008012071A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention comprises non occlusive compositions for transdermal delivery of nicotine, and more particularly pharmaceutically acceptable salts thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically comprise a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between about pH 5.5 and about pH 6.5. The compositions may include further components, for example, the hydroalcoholic vehicle may further comprise additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). The invention also relates to a method for the sustained delivery of nicotine pharmaceutically acceptable salts to treat a variety of conditions and disorders.
PCT/EP2007/006579 2006-07-24 2007-07-24 Pharmaceutical compositions of nicotine and methods of use thereof Ceased WO2008012071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/492,568 US7387788B1 (en) 2003-10-10 2006-07-24 Pharmaceutical compositions of nicotine and methods of use thereof
US11/492,568 2006-07-24

Publications (2)

Publication Number Publication Date
WO2008012071A2 WO2008012071A2 (en) 2008-01-31
WO2008012071A3 true WO2008012071A3 (en) 2008-03-13

Family

ID=38634394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/006579 Ceased WO2008012071A2 (en) 2006-07-24 2007-07-24 Pharmaceutical compositions of nicotine and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2008012071A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401912T3 (en) 2008-09-17 2013-04-25 Siegfried Ltd. Granulate containing nicotine
JP5820207B2 (en) 2011-09-13 2015-11-24 日東電工株式会社 Transdermal absorption enhancing composition and patch preparation
JP5820206B2 (en) 2011-09-13 2015-11-24 日東電工株式会社 Transdermal absorption enhancing composition and patch preparation
JP2013060393A (en) * 2011-09-13 2013-04-04 Nitto Denko Corp Composition for enhancing transdermal absorption and patch preparation
CN112444466B (en) * 2019-09-05 2023-02-28 上海新型烟草制品研究院有限公司 A method for evaluating the in vitro absorption of snus nicotine
CN113180282B (en) * 2021-05-07 2022-08-19 云南中烟工业有限责任公司 Fragrance-carrying supramolecular gel based on racemic nicotine tartrate gelling agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
EP1325752A2 (en) * 2000-08-03 2003-07-09 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1325752A2 (en) * 2000-08-03 2003-07-09 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANG J-Y ET AL: "EFFECT OF ADHESIVE AND DRUG RESERVOIR ON IN VITRO TRANSDERMAL DELIVERY OF NICOTINE", PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 54, no. 2, February 1999 (1999-02-01), pages 154 - 155, XP000799490, ISSN: 0031-7144 *

Also Published As

Publication number Publication date
WO2008012071A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2008005240A3 (en) Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof
WO2008012071A3 (en) Pharmaceutical compositions of nicotine and methods of use thereof
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2006026083A3 (en) Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
WO2008041246A3 (en) Injectable depot composition and its' process of preparation
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2006037116A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
EP1312366A8 (en) Aqueous pharmaceutical compositions
WO2007100910A3 (en) Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
CA2548897A1 (en) Endoparasiticidal agents for topical application
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2005087195A3 (en) Novel compositions for topical delivery
WO2008115385A3 (en) Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
WO2007098591A3 (en) Topical nail formulation
WO2001052897A3 (en) Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
WO2007092343A3 (en) Novel epoprostenol formulation and method of making thereof
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP3073991B1 (en) Topical pharmaceutical composition
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
WO2003068159A3 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2005080338A3 (en) New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07786305

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07786305

Country of ref document: EP

Kind code of ref document: A2